Wednesday, February 19, 2020
m8 Pharmaceuticals and Vectans Pharma, announced they have signed an exclusive licensing agreement whereby m8 will have the rights to register and commercialize Loramyc® (miconazole) for Mexico and Brazil. Loramyc® is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. Vectans received its first Loramyc® marketing authorization in France in October 2006. Loramyc® has since been registered in 26 European countries, in South Korea, Japan and in the United States amongst others.
Loramyc® is approved for the treatment of Oropharyngeal Candidiasis in immunocompromised patients, particularly those with head and neck cancers who have undergone radiotherapy, and those infected by HIV. Loramyc® is an innovative drug specifically developed for Oropharyngeal Candidiasis in immunodepressed patients, who frequently suffer an associated mucositis. Loramyc® offers an optimized anti-fungal treatment with the same order of efficacy as systemic therapies, with the advantage that it specifically targets the mouth and the oropharynx.
The new therapeutic approach uses an innovative delivery system based on a mucoadhesive buccal tablet (Lauriad®technology). This ensures an early and extended release of the active component at the site of the infection, with only one dose per day. The targeted approach reduces the risk of drug interactions and systemic effects, key issues for patients undergoing a multiplicity of treatments. The therapy is also designed to solve epidemiological and ecological problems caused by the emergence of resistant fungal infections.
m8 Pharmaceuticals continues its commitment to bringing innovative products to the Latin American region and this agreement reinforces its strategic focus in the area of oncology, further contributing to the supportive care of these patients in the region.
"We are very excited to be collaborating with Vectans Pharma on this innovative product. Oravig®/ Loramyc® has the potential to become the first targeted treatment in tablet form for oropharyngeal candidiasis in Mexico and Brazil, to provide an important addition to available treatments, and to maximize patients' compliance and improve their quality of life." said Joel Barlan, m8's CEO. Commenting on the agreement Jerome Theron, CEO of Vectans mentioned "This partnership is very relevant for us given Moksha8's expertise and leadership position in Mexico and Brazil. It is an important step in our development plan that reinforces our international strategy". Jérôme Théron, co-founder and CEO"
